Clinical characteristics of immune-related adverse events after immune checkpoint inhibitor therapy with or without chemotherapy in patients with antinuclear antibody-positive malignancies
BackgroundAntinuclear antibodies (ANA) are detected in cancer patients before ICI therapy, but their association with immune-related adverse events (irAEs) and outcomes is uncertain. This study aimed to characterize irAEs and tolerability in ANA-positi…